Invivyd Reaches Alignment With US FDA on Phase 3 Trial of VYD2311 for COVID Prevention

MT Newswires Live02-03 22:42

Invivyd (IVVD) said Tuesday it has achieved alignment with the US Food and Drug Administration for a phase 3 trial to evaluate the safety and immunologic profile of its VYD2311 investigational antibody to prevent COVID-19, compared with commercially available mRNA COVID vaccines.

The study will also assess the safety and immunology of VYD2311 and mRNA COVID vaccine given at the same time, the company said.

Invivyd said the FDA, citing "known risk" of myocarditis/pericarditis in young adult Americans following mRNA COVID vaccination, asked that adverse events of special interest be specifically monitored in the study.

Invivyd shares were up over 4% in early trading Tuesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2608487037?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-03 22:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608487037","market":"nz","top_or_hot":-1,"title":"Invivyd Reaches Alignment With US FDA on Phase 3 Trial of VYD2311 for COVID Prevention","media":"MT Newswires Live","content":"<html><body><p> Invivyd (IVVD) said Tuesday it has achieved alignment with the US Food and Drug Administration for a phase 3 trial to evaluate the safety and immunologic profile of its VYD2311 investigational antibody to prevent COVID-19, compared with commercially available mRNA COVID vaccines.</p><p>The study will also assess the safety and immunology of VYD2311 and mRNA COVID vaccine given at the same time, the company said.</p><p>Invivyd said the FDA, citing \"known risk\" of myocarditis/pericarditis in young adult Americans following mRNA COVID vaccination, asked that adverse events of special interest be specifically monitored in the study.</p><p>Invivyd shares were up over 4% in early trading Tuesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Invivyd Reaches Alignment With US FDA on Phase 3 Trial of VYD2311 for COVID Prevention</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInvivyd Reaches Alignment With US FDA on Phase 3 Trial of VYD2311 for COVID Prevention\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-03 22:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Invivyd (IVVD) said Tuesday it has achieved alignment with the US Food and Drug Administration for a phase 3 trial to evaluate the safety and immunologic profile of its VYD2311 investigational antibody to prevent COVID-19, compared with commercially available mRNA COVID vaccines.</p><p>The study will also assess the safety and immunology of VYD2311 and mRNA COVID vaccine given at the same time, the company said.</p><p>Invivyd said the FDA, citing \"known risk\" of myocarditis/pericarditis in young adult Americans following mRNA COVID vaccination, asked that adverse events of special interest be specifically monitored in the study.</p><p>Invivyd shares were up over 4% in early trading Tuesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2608487037","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608487037","pubTimestamp":1770129763,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Invivyd (IVVD) said Tuesday it has achieved alignment with the US Food and Drug Administration for a phase 3 trial to evaluate the safety and immunologic profile of its VYD2311 investigational antibod","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4539":"次新股","IVVD":"Invivyd, Inc."},"translate_title":"Invivyd与美国FDA就VYD2311预防新冠病毒的3期试验达成一致","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IVVD":1},"content_text":"Invivyd (IVVD) said Tuesday it has achieved alignment with the US Food and Drug Administration for a phase 3 trial to evaluate the safety and immunologic profile of its VYD2311 investigational antibody to prevent COVID-19, compared with commercially available mRNA COVID vaccines.The study will also assess the safety and immunology of VYD2311 and mRNA COVID vaccine given at the same time, the company said.Invivyd said the FDA, citing \"known risk\" of myocarditis/pericarditis in young adult Americans following mRNA COVID vaccination, asked that adverse events of special interest be specifically monitored in the study.Invivyd shares were up over 4% in early trading Tuesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608487037","isCrawlerRequest":true}